Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

  1. Koehm, Michaela
  2. McIntosh, Matthew J.
  3. Hofmann, Michael W.
  4. Abraham, Varghese
  5. Gabay, Cem
  6. Choy, Ernest H.
  7. Kavanaugh, Arthur
  8. Burkhardt, Harald
  9. Behrens, Frank

Download
s00296-020-04514-7.pdf 1,15MB
WeightNameValue
1000 Titel
  • Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
1000 Autor/in
  1. Koehm, Michaela |
  2. McIntosh, Matthew J. |
  3. Hofmann, Michael W. |
  4. Abraham, Varghese |
  5. Gabay, Cem |
  6. Choy, Ernest H. |
  7. Kavanaugh, Arthur |
  8. Burkhardt, Harald |
  9. Behrens, Frank |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-02-10
1000 Erschienen in
1000 Quellenangabe
  • 40(5):747-755
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00296-020-04514-7 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Assessment of individual therapeutic responses provides valuable information concerning treatment benefits in individual patients. We evaluated individual therapeutic responses as determined by the Disease Activity Score-28 joints critical difference for improvement (DAS28-d
1000 Sacherschließung
lokal Humans [MeSH]
lokal Rheumatoid arthritis
lokal Observational Research
lokal Severity of Illness Index [MeSH]
lokal Treatment Outcome [MeSH]
lokal Anti-rheumatic agents
lokal Arthritis, Rheumatoid/drug therapy [MeSH]
lokal Antibodies, Monoclonal, Humanized/administration
lokal Retrospective Studies [MeSH]
lokal Antirheumatic Agents/administration
lokal Patient Reported Outcome Measures [MeSH]
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Tocilizumab
lokal Treatment effectiveness
lokal Observational Studies as Topic [MeSH]
lokal Blood Sedimentation/drug effects [MeSH]
lokal Tumor Necrosis Factor Inhibitors/administration
lokal Patient outcome assessment
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S29laG0sIE1pY2hhZWxh|https://frl.publisso.de/adhoc/uri/TWNJbnRvc2gsIE1hdHRoZXcgSi4=|https://frl.publisso.de/adhoc/uri/SG9mbWFubiwgTWljaGFlbCBXLg==|https://frl.publisso.de/adhoc/uri/QWJyYWhhbSwgVmFyZ2hlc2U=|https://frl.publisso.de/adhoc/uri/R2FiYXksIENlbQ==|https://frl.publisso.de/adhoc/uri/Q2hveSwgRXJuZXN0IEgu|https://frl.publisso.de/adhoc/uri/S2F2YW5hdWdoLCBBcnRodXI=|https://frl.publisso.de/adhoc/uri/QnVya2hhcmR0LCBIYXJhbGQ=|https://frl.publisso.de/adhoc/uri/QmVocmVucywgRnJhbms=
1000 Hinweis
  • DeepGreen-ID: aae54b8356f041aebfe8e2761bd6ac82 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469212.rdf
1000 Erstellt am 2023-11-17T21:06:52.455+0100
1000 Erstellt von 322
1000 beschreibt frl:6469212
1000 Zuletzt bearbeitet 2023-12-01T09:26:22.515+0100
1000 Objekt bearb. Fri Dec 01 09:26:22 CET 2023
1000 Vgl. frl:6469212
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469212 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source